COST-CONSEQUENCE OF CLADRIBINE TABLETS FOR THE TREATMENT OF HIGHLY-ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) IN THE UK

被引：0
作者：
Miller, B. [1 ]
Russel-Szymczyk, M. [2 ]
Jensen, I. S. [3 ]
Shah, A. [1 ]
Alexopoulos, S. T. [4 ]
Herbert, A. [4 ]
McLean, T. [4 ]
Tundia, N. [5 ]
机构：
[1] Precis Hlth Econ & Outcomes Res, Grafton, MA USA
[2] Merck Sp Zoo, Affiliate Merck KGaA, Warsaw, Poland
[3] Precis Hlth Econ & Outcomes Res, Boston, MA USA
[4] Merck Serono Ltd, Affiliate Merck KGaA, Feltham, England
[5] EMD Serono Res & Dev Inst Inc, Affiliate Merck KGaA, Billerica, MA USA
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE658
引用
收藏
页码：S180 / S180
页数：1
相关论文
共 50 条
[21]   BUDGET IMPACT ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA [J].
Djambazov, S. ;
Slavchev, G. ;
Dineva, T. ;
Panayotov, P. ;
Vekov, T. .
VALUE IN HEALTH, 2018, 21 :S205-S205
[22]   Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands (vol 17, pg 857, 2019) [J].
Michels, Renee Else ;
De Francesco, Maria ;
Mahajan, Koshu ;
Hengstman, Gerald J. D. ;
Schiffers, Krijn M. H. ;
Budhia, Sangeeta ;
Harty, Gerard ;
Krol, Marieke .
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2020, 18 (01) :141-141
[23]   Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England [J].
Maruszczak, Maciej J. ;
Montgomery, Stephen M. ;
Griffiths, Matthew J. S. ;
Bergvall, Niklas ;
Adlard, Nicholas .
JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (11) :874-885
[24]   REGIONAL EFFICACY OF NATALIZUMAB TREATMENT IN RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) [J].
Doshi, Anisha ;
Voysey, Zanna ;
Bunting, Eva ;
Malik, Muzaffar ;
Rashid, Waqar .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2015, 86 (11)
[25]   Effect of cladribine tablets on brain atrophy rates in patients with relapsing-remitting multiple sclerosis (RRMS): exploratory analysis of the CLARITY study [J].
de Stefano, N. ;
Giorgio, A. ;
Battaglini, M. ;
Giovannoni, G. ;
Hicking, C. ;
Dangond, F. ;
Sormani, M. P. .
EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 :532-532
[26]   COST-EFFECTIVENESS OF CLADRIBINE TABLETS IN THE TREATMENT OF PATIENTS WITH HIGHLY ACTIVE RELAPSING MULTIPLE SCLEROSIS IN PORTUGAL [J].
Pinheiro, B. A. ;
Guerreiro, R. ;
Costa, J. ;
Silva Miguel, L. .
VALUE IN HEALTH, 2018, 21 :S339-S339
[27]   Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis [J].
Rosa Cortese ;
Giovanna Testa ;
Francesco Assogna ;
Nicola De Stefano .
CNS Drugs, 2024, 38 :267-279
[28]   Magnetic Resonance Imaging Evidence Supporting the Efficacy of Cladribine Tablets in the Treatment of Relapsing-Remitting Multiple Sclerosis [J].
Cortese, Rosa ;
Testa, Giovanna ;
Assogna, Francesco ;
De Stefano, Nicola .
CNS DRUGS, 2024, 38 (04) :303-314
[29]   Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets [J].
Signori, Alessio ;
Ponzano, Marta ;
Alexandri, Nektaria ;
Giovannoni, Gavin ;
Sormani, Maria Pia .
EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 (07) :2144-2147
[30]   Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis (vol 25, pg 239, 2011) [J].
Muir, Victoria J. ;
Plosker, Greg L. .
CNS DRUGS, 2020, 34 (04) :447-447
12345